Loading…
Loading…
Precursor conditions need careful risk assessment, not reflexive treatment
Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma are precursor plasma cell disorders. MGUS has a low annual risk of progression; smouldering myeloma has a higher risk that varies with disease burden and genetics. Most patients are monitored, while selected high-risk smouldering cases may be offered treatment or trials.
Haematology & Haemato-Oncology
Authored and reviewed by Dr. Sachita Baniya (MBBS, FCPS (Clinical Haematology), NMC 20158). Evidence-based, no fabricated outcomes.
Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma are precursor plasma cell disorders. MGUS has a low annual risk of progression; smouldering myeloma has a higher risk that varies with disease burden and genetics. Most patients are monitored, while selected high-risk smouldering cases may be offered treatment or trials.
Reviewed by Dr. Sachita Baniya, MBBS, FCPS — Consultant Haemato-Oncologist & Clinical Hematologist (NMC 20158). For evaluation, contact the respective hospital or cancer centre — Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital Kathmandu, or Advanced Care Hospital.
MGUS requires a serum M-protein below 30 g/L, marrow plasma cells below 10% and no myeloma-defining events. Smouldering myeloma meets the M-protein or marrow plasma cell threshold but lacks organ damage or defining biomarkers. Risk scores incorporate M-protein level, free light chain ratio, imaging and genetics to estimate progression.
Low-risk MGUS is usually monitored with blood and urine tests at intervals, with imaging or marrow assessment if new symptoms arise. Smouldering myeloma requires closer follow-up. Treatment is considered for high-risk smouldering disease in selected patients, preferably within a clinical trial, or when myeloma-defining events appear. Patients should understand the difference between a precursor and active cancer.
Guidelines referenced:
International Myeloma Working Group criteriaNCCN Guidelines — Multiple MyelomaMayo Clinic risk stratification for MGUSContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.